Identification and characterization of small molecules that inhibit nonsense-mediated rna decay and suppress nonsense p53 mutations

Cancer Research

Volumn 74, Issue 11, 2014, Pages 3104-3113

  Martin, Leenus ^a   Grigoryan, Arsen ^a   Wang, Ding ^a   Wang, Jinhua ^b   Breda, Laura ^a   Rivella, Stefano ^a   Cardozo, Timothy ^a   Gardner, Lawrence B ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; BINDING PROTEIN; BLOCKING AGENT; ETHYL 2 [[(6,7 DIMETHYL 3 OXO 1,2,3,4 TETRAHYDRO 2 QUINOXALINYL)ACETYL]AMINO] 4,5 DIMETHYL 3 THIOPHENECARBOXYLATE; METHYL 3 [[2 [(2 METHOXYBENZOYL)AMINO] 3 (3 NITROPHENYL)ACRYLOYL]AMINO]BENZOATE; N (3,4 DIMETHYLPHENYL) 2 [(4 METHYLPHENYL)AMINO] 6 OXO 1,4,5,6 TETRAHYDRO 4 PYRIMIDINECARBOXAMIDE; NMDI 14; NMDI 25; NMDI 9; PROTEIN P53; SMG7 PROTEIN; UNCLASSIFIED DRUG; UPF1 PROTEIN; CARRIER PROTEIN; MESSENGER RNA; MOLECULAR LIBRARY; SMG7 PROTEIN, HUMAN; STOP CODON; TP53 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; UPF1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL LINE; CELL DEATH; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; STOP CODON; TUMOR SUPPRESSOR GENE; UPREGULATION; CELL LINE; DRUG EFFECTS; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; HELA CELL LINE; MOLECULAR LIBRARY; PHARMACOLOGY; TUMOR CELL LINE;

CARRIER PROTEINS; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CODON, NONSENSE; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HUMANS; NONSENSE MEDIATED MRNA DECAY; RNA, MESSENGER; SMALL MOLECULE LIBRARIES; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84902125654     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2235     Document Type: Article

References (43)

1. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002;19:575-606.
2. Maquat LE, Kinniburgh AJ, Rachmilewitz EA, Ross J. Unstable betaglobin mRNA in mRNA-deficient beta o thalassemia. Cell 1981;27: 543-53.
3. Kan YW, Lee KY, Furbetta M, Angius A, Cao A. Polymorphism of DNA sequence in the beta-globin gene region Application to prenatal diagnosis of beta 0 thalassemia in Sardinia. N Engl J Med 1980;302:185-8.
4. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999;8:1893-900.
5. Gardner LB. Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis.Mol Cancer Res 2010;8:295-308.
6. Lykke-Andersen J, Shu MD, Steitz JA. Human Upf proteins target an mRNA for nonsense-mediated decay when bound downstream of a termination codon. Cell 2000;103:1121-31.
7. Lykke-Andersen J, Shu MD, Steitz JA. Communication of the position of exon-exon junctions to the mRNA surveillance machinery by the protein RNPS1. Science 2001;293:1836-9.
8. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002;30:13-9.
9. Czaplinski K, Ruiz-Echevarria MJ, Paushkin SV, Han X, Weng Y, Perlick HA, et al. The surveillance complex interacts with the translation release factors to enhance termination and degrade aberrant mRNAs. Genes Dev 1998;12:1665-77.
10. Okada-Katsuhata Y, Yamashita A, Kutsuzawa K, Izumi N, Hirahara F, Ohno S. N- And C-terminal Upf1 phosphorylations create binding platforms for SMG-6 and SMG-5:SMG-7 during NMD. Nucleic Acids Res 2012;40:1251-66.
11. Fukuhara N, Ebert J, Unterholzner L, Lindner D, Izaurralde E, Conti E. SMG7is a 14-3-3-like adaptor in the nonsense-mediatedmRNAdecay pathway. Mol Cell 2005;17:537-47.
12. Ohnishi T, Yamashita A, Kashima I, Schell T, Anders KR, Grimson A, et al. Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. Mol Cell 2003;12: 1187-200.
13. Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, et al. Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev 2006;20: 355-67.
14. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985;13:6265-72.
15. Salvatori F, Breveglieri G, Zuccato C, Finotti A, Bianchi N, Borgatti M, et al. Production of beta-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous beta(0)39 thalassemia patients. Am J Hematol 2009;84:720-8.
16. Floquet C, Deforges J, Rousset JP, Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011;39:3350-62.
17. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-9.
18. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997;3:1280-4.
19. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349: 1433-41.
20. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91.
21. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009;22:532-8.
22. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007;117:683-92.
23. Ishigaki Y, Li X, Serin G, Maquat LE. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell 2001;106: 607-17.
24. Dang Y, Low WK, Xu J, Gehring NH, Dietz HC, Romo D, et al. Inhibition of nonsense-mediated mRNA decay by the natural product pateamine A through eukaryotic initiation factor 4AIII. J Biol Chem 2009;284: 23613-21.
25. Gardner LB. Hypoxic inhibition of nonsense-mediated RNA decay regulates gene expression and the integrated stress response. Mol Cell Biol 2008;28:3729-41.
26. Wang D, Zavadil J, Martin L, Parisi F, Friedman E, Levy D, et al. Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. Mol Cell Biol 2011;31: 3670-80.
27. Cardozo T, Abagyan R. Druggability of SCF ubiquitin ligase-protein interfaces. Methods Enzymol 2005;399:634-53.
28. Abagyan R, Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 1994;235:983-1002.
29. Martin L, Kimball SR, Gardner LB. Regulation of the unfolded protein response by eif2bdelta isoforms. J Biol Chem 2010;285:31944-53.
30. Martin L, Rainey M, Santocanale C, Gardner LB. Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation. Oncogene 2012;31:4076-84.
31. Wengrod J, Martin L, Wang D, Frischmeyer-Guerrerio P, Dietz HC, Gardner LB. The inhibition of nonsense mediated RNA decay activates autophagy. Mol Cell Biol 2013;33:2128-35.
32. Chang JC, Kan YW. Beta 0 thalassemia, a nonsense mutation in man. Proc Natl Acad Sci U S A 1979;76:2886-9.
33. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet 2004;36: 1073-8.
34. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, et al. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992;7:171-80.
35. Wang CS, Goulet F, Lavoie J, Drouin R, Auger F, Champetier S, et al. Establishment and characterization of a new cell line derived from a human primary breast carcinoma. Cancer Genet Cytogenet 2000;120: 58-72.
36. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991;51: 4090-6.
37. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
38. Gabrilovich DI. INGN 201 (Advexin): Adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 2006;6:823-32.
39. Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, et al. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS ONE 2013;8:e60478.
40. Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, Bertrand E, et al. Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol 2007;178:1145-60.
41. Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K, et al. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis 2012;7:58.
42. Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Monch K, Thoren LA, Nielsen FC, et al. NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. Genes Dev 2008;22:1381-96.
43. Frischmeyer-Guerrerio PA, Montgomery RA, Warren DS, Cooke SK, Lutz J, Sonnenday CJ, et al. Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice. Proc Natl Acad Sci U S A 2011;108:10638-43.